Literature DB >> 15789794

Jaundice as a presentation of phenol induced hepatotoxocity following injection sclerotherapy for haemorrhoids.

A Suppiah1, E P Perry.   

Abstract

A 43-year-old man was admitted with jaundice six days following phenol injection sclerotherapy for haemorrhoids. He was diagnosed with a phenol-induced hepatitis. Although he remained well, liver function tests only returned to normal after six months. Systemic absorption of phenol has been reported with ingestion, upper airway and excessive cutaneous exposure but not as a complication of haemorrhoidal injection sclerotherapy. Hepatic involvement is also rare and usually the result of ongoing sepsis. We report the unique case of a patient presenting with jaundice secondary to chemical hepatitis, following systemic absorption of phenol at injection sclerotherapy. This case highlights the importance of clinical awareness of not only the infective complications of injection sclerotherapy but also the potential for phenol to be absorbed systemically with severe consequences. A brief overview of symptoms of phenol toxicity is included.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15789794     DOI: 10.1016/s1479-666x(05)80011-3

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  3 in total

1.  The non-surgical management for hemorrhoidal disease. A systematic review.

Authors:  G Cocorullo; R Tutino; N Falco; L Licari; G Orlando; T Fontana; C Raspanti; G Salamone; G Scerrino; G Gallo; M Trompetto; G Gulotta
Journal:  G Chir       Date:  2017 Jan-Feb

2.  Polidocanol versus phenol in oil injection sclerotherapy in treatment of internal hemorrhoids: A randomized controlled trial.

Authors:  Sandeep Mishra; Ashok Kumar Sahoo; Thirthar Palanivelu Elamurugan; Sadasivan Jagdish
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

Review 3.  Sclerotherapy in Hemorrhoids.

Authors:  Anling He; Mingkai Chen
Journal:  Indian J Surg       Date:  2022-04-20       Impact factor: 0.437

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.